Lexaria Bioscience通过为研发提供资金的股票和为其药物供应平台的商业增长筹集了4M美元。 Lexaria Bioscience raised $4M through a stock offering to fund R&D and business growth for its drug delivery platform.

Lexaria生物科学公司关闭了价值400万美元的股票销售,出售270万股,每股1.5美元,同时签发许可证,购买相同数目的股票,每股1.37美元。 Lexaria Bioscience Corp. closed a $4.0 million stock offering, selling 2.7 million shares at $1.50 each, with concurrent warrants to buy the same number of shares at $1.37 each. 这些收益在支出之前,将为2026年的周转资金、研发和企业发展提供资金。 The proceeds, before expenses, will fund working capital, R&D, and business development for 2026. 由H.C. Wainwright & Co.在2025年1月生效的储存登记下管理的这项提议支持该公司的DehidaTECHTM药物供应平台,该平台的目的是改善口服药物吸收和血液阻塞渗透。 The offering, managed by H.C. Wainwright & Co. under a shelf registration effective since January 2025, supports the company’s DehydraTECH™ drug delivery platform, which aims to improve oral drug absorption and blood-brain barrier penetration. Lexaria拥有全球50项被授予的专利,并继续推进其技术。 Lexaria holds 50 granted patents globally and continues advancing its technology.